STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Kyverna’s cell therapy shows lasting autoimmune benefitWorldPing
Image via STAT.

What happened

Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…

Key facts

  • Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…
  • Reported by STAT and published Thu, 24 Sep 2026 13:52:10 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Related WorldPing coverage